Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 7/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | BRS3 | P32247 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11426539 | 0.87 | RORC (0.51) | RORCCNR2CYP4F2CYP4A11BRS3 | |
| SCHEMBL14393384 | 0.87 | RORC (0.51) | RORCCNR2CYP4F2CYP4A11BRS3 | |
| SCHEMBL1125293 | 0.87 | RORC (0.51) | RORCCNR2CYP4F2CYP4A11MMP8 | |
| SCHEMBL992232 | 0.86 | CYP4F2 (0.57) | RORCCNR2CYP4F2CYP4A11BRS3 | |
| SCHEMBL27796483 | 0.84 | BRS3 (0.53) | RORCKMT2AMEN1CNR2CYP4F2 | |
| SCHEMBL8434856 | 0.83 | RORC (0.53) | RORCCNR2MMP8OPRK1ABCB11 | |
| Hydrochloric Acid SCHEMBL11110222 | 0.83 | RORC (0.48) | RORCKMT2ACNR2CYP4F2CYP4A11 | |
| SCHEMBL6580520 | 0.82 | PPARA (0.46) | RORCCNR2CYP4F2CYP4A11MMP8 | |
| SCHEMBL20621008 | 0.82 | RORC (0.52) | RORCCNR2CYP4F2CYP4A11MMP8 | |
| SCHEMBL8880235 | 0.81 | MMP8 (0.44) | KMT2AMEN1CNR2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024272-A | Process for producing 2-methyl-2-phenylpropionic acid derivative | 住友化学株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-4177248-A1 | A CLASS OF TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Hefei Institute of Pharmaceutical Industry Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| EP-4177248-A1 | A CLASS OF TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Hefei Institute of Pharmaceutical Industry Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-20230140276-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | HEFEI AMVITE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230140276-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | HEFEI AMVITE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230140276-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | HEFEI AMVITE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| CN-115427405-A | Tricyclic compound, preparation method and medical application thereof | 合肥医工医药股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-113979960-B | Preparation method of bilastine intermediate | 南京桦冠生物技术有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-113979960-A | Preparation method of bilastine intermediate | 南京桦冠生物技术有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2022001331-A1 | A CLASS OF TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 合肥医工医药股份有限公司 | 2022-01-06 | — | — | WO | disclosed |
| CN-106349214-A | Method for preparing bilastine impurity | 南京长澳医药科技有限公司 | 2017-01-25 | — | — | CN | disclosed |
| EP-0956286-B1 | SYNTHESIS OF TERFENADINE AND DERIVATIVES | SEPRACOR INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6147217-A | Synthesis of terfenadine and derivatives | SEPRACOR INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0956286-A1 | SYNTHESIS OF TERFENADINE AND DERIVATIVES | SEPRACOR, INC. (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5925761-A | Synthesis of terfenadine and derivatives | SEPRACOR INC. (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1998033789-A1 | SYNTHESIS OF TERFENADINE AND DERIVATIVES | SEPRACOR, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140276-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | HNMT, CHRM1, HRH4 | RORC 691/4885KMT2A 359/4885MEN1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.